Banking Crisis Prompts Postponed Noile-Immune IPO, But Wider Japan Views Mixed

 
• By Lisa Takagi

While the SVB and wider banking crisis has shaken VCs and bioventures in the US and Europe, Japan has mixed view on its impact and the government is keeping an eye on the situation. But one biotech has nevertheless cautiously decided to withdraw from a market listing despite Tokyo Exchange Market approval.

Although not fearing the direct impact from the global banking crisis, Japan’s biotech/bioventure market in in a cautious for its potential impact.
Although not fearing the direct impact from the global banking crisis, Japan’s biotech/bioventure market is in a cautious for its potential impact. • Source: Shutterstock

More from Japan

More from Focus On Asia